HIGHLIGHTS
- who: Kimberly D. Herman from the Universitéde Montréal, Canada Setsunan University, Japan have published the research: The EGFR/ErbB inhibitor neratinib modifies the neutrophil phosphoproteome and promotes apoptosis and clearance by airway macrophages, in the Journal: (JOURNAL)
- what: To determine whether neratinib treatment altered the damage to the lung tissue observed in this model, histological analysis was carried out on lung tissue slices . The authors show that neratinib, an ErbB inhibitor used to treat breast cancer, may be able to reduce acute inflammation in the lungs, by reducing the number of neutrophil corpses . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.